Skip to main content

Titan Pharmaceuticals, Inc. (TTNP)

NASDAQ: TTNP · IEX Real-Time Price · USD
1.28 0.02 (1.59%)
Dec 3, 2021 4:00 PM EST - Market closed

Company Description

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases.

It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on the treatment for chronic diseases. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union.

It is also developing kappa opioid agonist peptide program, TP-2021 for use in combination with ProNeura technology for treatment of chronic pruritus; nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including non-clinical evaluation of the ProNeura platform in malaria prophylaxis.

Titan Pharmaceuticals, Inc. was incorporated in 1992 and is based in South San Francisco, California.

Titan Pharmaceuticals, Inc.
Titan Pharmaceuticals Logo
CountryUnited States
IPO DateJan 18, 1996
IndustryPharmaceuticals
SectorHealth Care
Employees12

Contact Details

Address:
400 Oyster Point Blvd Ste 505
South San Francisco, California 94080-1958
United States
Phone650 244 4990
Websitetitanpharm.com

Stock Details

Ticker SymbolTTNP
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
CIK Code0000910267

Key Executives

NamePosition
Dr. Marc Rubin M.D.Executive Chairman and Principal Executive Officer
Dr. Katherine L. Beebe-DeVarney Ph.D.President, Chief Operating Officer and Director
Brian E. CrowleyVice President of Finance
Mike FritzNational Sales Director
Jennifer KiernanExecutive Assistant to Chief Executive Officer and Investor Communications Coordinator
Joe SchreiExecutive Director of Commercial Operations

Latest SEC Filings

DateTypeTitle
Nov 19, 2021DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Nov 15, 202110-QQuarterly report [Sections 13 or 15(d)]
Nov 9, 20218-KCurrent report
Nov 5, 2021DEF 14AOther definitive proxy statements
Oct 27, 20218-KCurrent report
Oct 25, 20218-KCurrent report
Aug 16, 202110-QQuarterly report [Sections 13 or 15(d)]
Jul 26, 20218-KCurrent report
May 17, 202110-QQuarterly report [Sections 13 or 15(d)]
Mar 31, 202110-KAnnual report [Section 13 and 15(d), not S-K Item 405]
View All SEC Filings